MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • 2024 International Congress

    Comorbid Tardive Dyskinesia (TD) and Restless Leg Syndrome (RLS)

    V. Chang, T. Stiep (San Francisco, USA)

    Objective: To describe an unusual co-occurrence of disorders involving dopaminergic dysregulation. Background: TD and RLS result from opposing abnormalities in dopaminergic transmission pathways in the…
  • 2024 International Congress

    Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report

    H. Oktaviani, A. Tiksnadi, D. Tunjungsari (Jakarta, Indonesia)

    Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…
  • 2024 International Congress

    Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss

    S. Jha (Kolkata, India)

    Objective: To describe a case of proven Hashimoto Encephalopathy presenting with oromandibular dystonia (OMD) and orofacial dyskinesias (OFD) Background: Neurologic manifestations of Hashimoto’s Encephalopathy (HE)…
  • 2024 International Congress

    Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data

    R. Mehanna, R. Hauser, E. Furr Stimming, L. Citrome, E. Kayson, J. Goldstein, O. Klepitskaya, S. Hinton, H. Zhang, E. Dunayevich, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To assess the treatment effect size of once-daily valbenazine for tardive dyskinesia (TD) and for chorea associated with Huntington’s disease (HD) using data from…
  • 2024 International Congress

    Patient and Caregiver Experiences with Tardive Dyskinesia: Emotions, Challenges, and Unmet Needs in the Patient Journey

    A. Peyser Levin, E. Kinjo, R. Ribalov, N. Chaijale, A. Yaari (Tel Aviv, Israel)

    Objective: To describe the emotional journey from symptom onset to current state and identify challenges and unmet needs of participants living with tardive dyskinesia (TD)…
  • 2024 International Congress

    Effectiveness of Deutetrabenazine for Tardive Dyskinesia When Initiated Using a 4-Week Patient Titration Kit: Final Results of the START Study

    K. Anderson, M. Konings, S. Finkbeiner, J. Bennett, M. Asim Nisar, G. Alva, A. Cutler (Washington, USA)

    Objective: To evaluate the effectiveness, dosing patterns, and patient treatment satisfaction in patients with tardive dyskinesia treated with deutetrabenazine using a 4-week titration kit. Background:…
  • 2024 International Congress

    Drug-Induced Parkinsonism and Tardive Dyskinesia in Rats Chronically Treated with Haloperidol

    H. Hikichi, H. Nishijima, F. Mori, I. Kinoshita, C. Murakami, M. Tomiyama (Hirosaki, Japan)

    Objective: To reproduce the side effects of antipsychotic drugs (drug-induced Parkinsonism and tardive dyskinesia) in rats and elucidate its pathomechanism by examining morphological changes in…
  • 2024 International Congress

    GPR30 agonists attenuate haloperidol-induced neurotoxicity in SH-SY5Y cells and adult zebrafish.

    SHU. Upadhayay, PKB. Kumar (Baathinda, India)

    Objective: Objective:1. To investigate the neuroprotective effect of FDA-approved compounds (Raloxifene and Fulvestrant) against haloperidol-induced neurotoxicity in SHSY-5Y cells and adult zebrafish2. To explore the molecular…
  • 2024 International Congress

    Bistriatal hypermetabolism on 18-FDG PET-CT in tardive dyskinesia

    C. Héraud, C. Alecu, C. Giordana (NICE, France)

    Objective: Tardive dyskinesia (TD) describes various movement disorders developing after treatment with dopamine receptor blocking agents (DRBA), including stereotypy, akathisia, dystonia, tremor, tics and chorea.…
  • 2024 International Congress

    Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach

    M. Hildaria, D. Tunjungsari, A. Tiksnadi (Central Jakarta, Indonesia)

    Objective: To report a case of tardive dystonia induced by risperidone and discuss the therapeutic approach, including the use of botulinum toxin. Background: Risperidone, a…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley